Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Howard Huaihan Pai1,5, Brenna Eldridge2,
Darcy Bishop3,
Abraham Alexander1,5, Mary Lesperance4,
Paul Blood1,5,
Jan Lim1,5, Charles Ludgate1,5
Canadian Journal of Urology, Vol.16, No.2, pp. 4541-4552, 2009
Abstract Purpose: To assess outcome and predictive factors in men with prostate cancer who receive post radical prostatectomy (RP) radiotherapy (RT) either in the adjuvant or salvage setting, with or without neoadjuvant androgen deprivation therapy (NADT).
Methods: A retrospective analysis was performed on 175 patients with clinically localized prostate cancer treated with RP who subsequently received RT (dose range 50 Gy-68 Gy). Twenty-two patients received adjuvant RT (ART), 57 received NADT + ART, 15 received salvage RT (SRT), and 81 received NADT + SRT. Outcome was assessed by biochemical disease-free survival (BDFS), prostate cancer specific survival and overall… More >